PMID: 37544Apr 25, 1979Paper

GABAergic and glycinergic mechanisms within the substantia nigra: pharmacological specificity of dopamine-independent contralateral turning behavior and interactions with other neurotransmitters

Psychopharmacology
J Arnt, J Scheel-Krüger

Abstract

The pharmacological specificity of the GABA agonist muscimol-induced contralateral turning behavior after unilateral injection into substantia nigra pars reticulata (SNR) has been studied. Muscimol-induced turning was antagonized by intranigral bicuculline methochloride (BMC) and picrotoxin, whereas antagonists of glycine, morphine, dopamine, noradrenaline, and serotonin were ineffective. Glycine induced a qualitatively similar turning behavior which was strychnine-sensitive but relatively BMC and picrotoxin-insensitive. Other drugs, including substance P, kainic acid, clonidine, oxymetazoline, serotonin, and carbachol, induced turning that could be dissociated from the effect of muscimol. Muscimol-induced turning was dopamine-independent, indicated by resistance to haloperidol (1 mg/kg), to pretreatment with reserpine (7.5 mg/kg) plus alpha-methyl-p-tyrosine (200 mg/kg), to haloperidol injections into the SNR, striatum and nucleus accumbens, and finally to kainic acid lesions of the striatum. 6-Hydroxydopamine lesions increased the efficacy of intranigral muscimol, while kainic acid lesions of the SNR antagonized muscimol. Muscimol-induced turning was inhibited by oxotremorine (0.25 mg/kg), by intranigral carbachol, and by apo...Continue Reading

References

Apr 1, 1976·The Journal of Pharmacy and Pharmacology·A Dray, D W Straughan
Aug 1, 1976·The Journal of Physiology·A DrayN R Oakley
Mar 1, 1977·The Journal of Pharmacy and Pharmacology·T A James, M S Starr
May 27, 1977·Brain Research·R Schwarcz, J T Coyle
Sep 1, 1977·Life Sciences·S Berthelsen, W A Pettinger
Jan 1, 1978·Annual Review of Pharmacology and Toxicology·G A Johnston
Jan 15, 1978·European Journal of Pharmacology·C J Pycock, C D Marsden
Dec 1, 1978·Journal of Neurochemistry·G A JohnstonD Lodge
Jun 15, 1977·European Journal of Pharmacology·C OberlanderJ R Boissier
Jan 1, 1979·European Journal of Pharmacology·G M De MontisJ Scheel-Krüger
Jan 15, 1978·European Journal of Pharmacology·A ChéramyJ Glowinski
May 1, 1976·Life Sciences·S D GlickL N Fleisher
Jan 27, 1977·Nature·M Garcia-MunozG W Arguthnott
Dec 17, 1976·Brain Research·E G McGeerP L McGeer
May 16, 1975·Brain Research·D TarsyC D Marsden
Jan 1, 1976·Experimental Neurology·J S MendezK E Dahl
Jan 1, 1976·British Journal of Pharmacology·R G HillD W Straughan
May 14, 1976·Brain Research·J Davies, A Dray
Aug 24, 1973·Naunyn-Schmiedeberg's Archives of Pharmacology·N E Andén, G Stock
Jan 1, 1972·Psychopharmacologia·C Broekkamp, J M van Rossum
Mar 1, 1974·European Journal of Pharmacology·L TuomistoE E Smissman
Mar 1, 1971·Journal of Neurochemistry·T L PerryC Mok
May 29, 1981·Neuroscience Letters·G M De MontisA Tagliamonte
Oct 1, 1980·Pharmacology, Biochemistry, and Behavior·M R Kozlowski, J F Marshall

❮ Previous
Next ❯

Citations

Jan 1, 1980·Psychopharmacology·S Kaakkola, I Kääriäinen
Dec 1, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·J Arnt, J Scheel-Krüger
Aug 1, 1981·Naunyn-Schmiedeberg's Archives of Pharmacology·S WolfarthK H Sontag
Jan 1, 1992·Experimental Brain Research·H Condé
Mar 7, 1980·European Journal of Pharmacology·J Arnt, J Scheel-Krüger
Feb 19, 1981·European Journal of Pharmacology·I C Kilpatrick, M S Starr
Oct 22, 1982·European Journal of Pharmacology·C D Andrews, G N Woodruff
Aug 25, 1995·European Journal of Pharmacology·A P Wickens, R G Pertwee
Jun 15, 1981·Life Sciences·C J Pycock, R W Kerwin
Dec 1, 1994·Toxicon : Official Journal of the International Society on Toxinology·V A Dorce, M R Sandoval
Sep 1, 1996·Pharmacology, Biochemistry, and Behavior·C A Hawkins, S A Greenfield
Jan 1, 1983·Neurochemistry International·F V Defeudis
Jan 1, 1980·Neuroscience·C J Pycock
Jan 1, 1995·Brain & Development·S L MoshéL L Brown
Jun 20, 2001·Journal of Neuroendocrinology·M L OvesjöB Meister
Feb 11, 1998·Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society·S L Moshé
Jan 1, 1990·Annals of the New York Academy of Sciences·L A ThompsonJ M Walker
Jan 1, 1983·Psychopharmacology·N BjørndalE Christensson
Dec 22, 2004·Epilepsia·Jana VelískováSolomon L Moshé

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here